Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

258 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Reinstated p53 response and high anti-T-cell leukemia activity by the novel alkylating deacetylase inhibitor tinostamustine.
Pützer S, Varghese L, von Jan J, Braun T, Giri AK, Mayer P, Riet N, Timonen S, Oberbeck S, Kuusanmäki H, Mustjoki S, Stern MH, Aittokallio T, Newrzela S, Schrader A, Herling M. Pützer S, et al. Among authors: aittokallio t. Leukemia. 2020 Sep;34(9):2513-2518. doi: 10.1038/s41375-020-0772-6. Epub 2020 Feb 25. Leukemia. 2020. PMID: 32099034 Free article. No abstract available.
Enhanced sensitivity to glucocorticoids in cytarabine-resistant AML.
Malani D, Murumägi A, Yadav B, Kontro M, Eldfors S, Kumar A, Karjalainen R, Majumder MM, Ojamies P, Pemovska T, Wennerberg K, Heckman C, Porkka K, Wolf M, Aittokallio T, Kallioniemi O. Malani D, et al. Among authors: aittokallio t. Leukemia. 2017 May;31(5):1187-1195. doi: 10.1038/leu.2016.314. Epub 2016 Nov 11. Leukemia. 2017. PMID: 27833094 Free PMC article.
Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling.
Andersson EI, Pützer S, Yadav B, Dufva O, Khan S, He L, Sellner L, Schrader A, Crispatzu G, Oleś M, Zhang H, Adnan-Awad S, Lagström S, Bellanger D, Mpindi JP, Eldfors S, Pemovska T, Pietarinen P, Lauhio A, Tomska K, Cuesta-Mateos C, Faber E, Koschmieder S, Brümmendorf TH, Kytölä S, Savolainen ER, Siitonen T, Ellonen P, Kallioniemi O, Wennerberg K, Ding W, Stern MH, Huber W, Anders S, Tang J, Aittokallio T, Zenz T, Herling M, Mustjoki S. Andersson EI, et al. Among authors: aittokallio t. Leukemia. 2018 Mar;32(3):774-787. doi: 10.1038/leu.2017.252. Epub 2017 Aug 14. Leukemia. 2018. PMID: 28804127
Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target.
Dufva O, Kankainen M, Kelkka T, Sekiguchi N, Awad SA, Eldfors S, Yadav B, Kuusanmäki H, Malani D, Andersson EI, Pietarinen P, Saikko L, Kovanen PE, Ojala T, Lee DA, Loughran TP Jr, Nakazawa H, Suzumiya J, Suzuki R, Ko YH, Kim WS, Chuang SS, Aittokallio T, Chan WC, Ohshima K, Ishida F, Mustjoki S. Dufva O, et al. Among authors: aittokallio t. Nat Commun. 2018 Apr 19;9(1):1567. doi: 10.1038/s41467-018-03987-2. Nat Commun. 2018. PMID: 29674644 Free PMC article.
DNMT Inhibitors Increase Methylation in the Cancer Genome.
Giri AK, Aittokallio T. Giri AK, et al. Among authors: aittokallio t. Front Pharmacol. 2019 Apr 24;10:385. doi: 10.3389/fphar.2019.00385. eCollection 2019. Front Pharmacol. 2019. PMID: 31068808 Free PMC article.
Genome-wide off-targets of drugs: risks and opportunities.
Giri AK, Ianevski A, Aittokallio T. Giri AK, et al. Among authors: aittokallio t. Cell Biol Toxicol. 2019 Dec;35(6):485-487. doi: 10.1007/s10565-019-09491-7. Epub 2019 Aug 20. Cell Biol Toxicol. 2019. PMID: 31432301 No abstract available.
258 results